Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 3Leukemia, Myeloid, Acute 3Dendritic Cell Sarcoma, Interdigitating 3Sarcoma, Myeloid 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Waldenstrom Macroglobulinemia 1Sarcoma 1Recurrence 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Neoplasms 1Colorectal Neoplasms 1Chondrosarcoma 1

Interventions

Cyclophosphamide 76fludarabine phosphate 42Filgrastim 38Peripheral Blood Stem Cell Transplantation 35Radiotherapy 33Cyclosporine 32Busulfan 32Mycophenolic Acid 30Etoposide 30Antilymphocyte Serum 28Whole-Body Irradiation 26Methotrexate 25Rituximab 22Melphalan 21Methylprednisolone 20Vincristine 17Tacrolimus 17Cytarabine 17Cord Blood Stem Cell Transplantation 17Doxorubicin 16Prednisone 15Thiotepa 10Granulocyte Colony-Stimulating Factor 9Carboplatin 8Leucovorin 7fludarabine 6aldesleukin 6Ifosfamide 6sargramostim 5Sirolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Dendritic Cell Sarcoma, Interdigitating × venetoclax × Sarcoma × Clear all
NCT03740529 2026-01-27

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Eli Lilly and Company

Phase 1/2 Completed
803 enrolled 2 FDA
LymphoidOther hematologic neoplasmSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT03064867 2022-11-16

Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Case Comprehensive Cancer Center

Phase 1/2 Active not recruiting
65 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT03886649 2022-04-01

Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

Swiss Cancer Institute

Phase 1 Terminated
7 enrolled
LymphoidSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡